Study: Chemo Drug May Hike Tumor Immunity
Posted on: Monday, 19 February 2007, 12:00 CST
U.S. scientists have discovered a chemotherapy drug might enhance patients' immunity to tumors, helping them to more effectively fight the disease.
Rockefeller University researchers have found that a chemotherapy drug called bortezomib can kill multiple myeloma cells -- cancer in immune cells in bone marrow -- in culture in such a way that it elicits a response by memory and killer T cells.
Until recently it's been thought radiation therapy and various forms of chemotherapy were separate but equal treatments. Now, however, new research is beginning to show it's not just killing the cancer cells that matters -- it's also important as to how they are killed.
A study by Associate Rockefeller University Professor Madhav Dhodapkar, postgraduate fellow Radek Spisek and colleagues shows bortezomib kills tumor cells in such a way that it might allow the immune system to recognize them.
The study is detailed online in the journal Blood.
Source: United Press International
Related Articles
- Prediction Model Superior To Traditional Criteria In Bladder Treatment Decision
- Antibody Linked To Chemotherapy Drug Inhibits Ovarian Cancer In Lab
- Seattle Genetics Initiates SGN-40 Phase IIb Clinical Trial in Combination With Rituxan and Chemotherapy for Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- V Foundation Partners With St. Helena Hospital Foundation to Raise Funds for New Cancer Center at St. Helena Hospital
- Study Says Chemotherapy Kills Healthy Brain Cells
- St. Helena Hospital and SHH Foundation Announce
- A Moment With Clay Siegall, President and Ceo of Seattle Genetics
- Both Inherited Traits and Tumor Mutations Affect Response to Treatment of Acute Lymphoblastic Leukemia
- Executive Summary Report1
- Normal Bone Marrow Stem Cells Might Be More Vulnerable to Toxic Chemotherapy When a Protective Molecule is Disabled
 |
 |
User Comments (0)
RSS Feeds